The cost of inaction: what happens when medication risk goes unmanaged

Quantifying the cost impact of delayed medication intervention in insurance claims

Published 3 April 2026

Introduction

Insurance claim managers face continuous budget pressures and competing expenditure demands. Medication review and intervention can feel discretionary in the face of immediate claim expenses. However, deferring medication intervention extracts a substantial hidden cost. Unmanaged medication risk creates escalating claim expenses, extended claim duration, and compounding functional deterioration that ultimately costs significantly more than early intervention.

Understanding the true cost of medication inaction versus intervention cost is essential to optimal claim budgeting and financial decision-making. This article quantifies the cost consequences of unmanaged medication risk and provides cost-benefit analysis for medication intervention timing.

The Escalation Patterns of Unmanaged Medication Risk

Medication Cost Escalation

Unmanaged medication risk leads to progressive cost escalation through multiple mechanisms: dose escalation (tolerance development or worsening symptom attribution to disease rather than medication), medication additions (cascade prescribing addressing medication-induced side effects), and medication switching (trial-and-error approaches when underlying regimen complexity is not addressed).

Typical escalation pattern: Month 1-3 medication cost AUD 1,500-2,000. Months 4-6 escalation to AUD 2,500-3,500 (30-40% increase). Months 7-12 escalation to AUD 3,500-4,500 (additional 25-35% increase). Over 12 months, unmanaged medication cost escalation totals AUD 30,000-50,000 per claim.

Secondary Cost Escalation: Medical Consultations

Unmanaged medication risk creates increasing medical consultation needs as medication-related complications develop: additional GP consultations addressing emerging side effects, specialist consultations for symptoms misattributed to disease progression, emergency department presentations for medication-related adverse events.

Typical pattern: Months 1-3 consultation cost AUD 400-600 monthly. Months 4-12 escalation to AUD 800-1,200 monthly as medication complications accumulate. Annual escalation: AUD 2,400-3,600 additional consultation cost beyond baseline.

Functional Deterioration Costs

Most significant cost impact of medication inaction is functional deterioration. Unmanaged polypharmacy, medication cascade effects, and side effect burden impair cognitive and physical function, delaying return-to-work and extending claim duration. Claimants with unmanaged medication risk have average return-to-work delay of 8 to 16 weeks compared to claimants receiving medication intervention.

Cost of return-to-work delay: AUD 500-1,500 weekly claim cost (depending on entitlement level and jurisdiction). 8-16 week delay = AUD 4,000-24,000 claim extension cost.

Real-World Cost Comparison: Intervention vs. Inaction

Case Study 1: Polypharmacy Cost Impact

Scenario: Workers compensation claimant, 6 months post-injury, on 7 medications. Claim manager declines medication review (estimated cost AUD 1,000) due to budget constraints.

12-Month Outcome with No Intervention: Medication escalation to 9 medications, monthly cost increasing from AUD 350 to AUD 520. Additional medications include second antidepressant (added for inadequate response) and sleeping tablet (added for polypharmacy-related insomnia). Two falls due to polypharmacy-related dizziness requiring emergency department presentation and imaging (AUD 2,500). Return-to-work delayed from Month 9 to Month 15 (6-month delay) due to cognitive impairment and falls. Total claim cost extension: AUD 6,000-8,000.

Alternative 12-Month Outcome with Medication Review (AUD 1,000 cost): Medication review identifies 3 deprescribing candidates. Structured deprescribing over 8 weeks reduces medications from 7 to 4. Monthly medication cost reduces from AUD 350 to AUD 150. Cognitive function improves post-deprescribing enabling work participation by Month 8. One planned fall prevention intervention implemented preventing subsequent falls. Total claim cost reduction: AUD 3,000-4,000 (medication cost plus earlier return-to-work). Net cost benefit of intervention: AUD 3,000-4,000 minus AUD 1,000 intervention cost = AUD 2,000-3,000 net savings.

Case Study 2: Opioid Escalation Cost Impact

Scenario: CTP claim, chronic pain, opioid therapy initiated at 3 months post-injury. Claim manager declines medication review to focus on physiotherapy funding.

24-Month Outcome with No Medication Intervention: Opioid dose escalates from oxycodone 20mg three times daily (initial) to 40mg four times daily by Month 18. Concurrent medications added: laxatives and stool softeners (AUD 50/month), muscle relaxant (AUD 35/month), sleep agent (AUD 30/month). Additional prescriber consultations monthly to assess pain control (AUD 100/month). Psychological assessment requested due to depression (AUD 300). Medication cost Month 1-6: AUD 60/month. Month 7-12: AUD 150/month. Month 13-24: AUD 280/month. Average annual medication cost: AUD 165/month. 24-month medication cost: AUD 3,960. Additional consultation and assessment cost: AUD 2,400. Return-to-work delayed from Month 12 to Month 22 (10-month delay at AUD 1,000/month = AUD 10,000 claim extension). Total 24-month cost: AUD 16,360.

Alternative 24-Month Outcome with Medication Review at Month 6 (AUD 1,200 cost): Medication review at Month 6 identifies inadequate pain management on current opioid dose and non-opioid pain management opportunities. Recommendation to transition to multimodal pain approach: opioid stabilisation (preventing further escalation), structured physiotherapy (focusing on pain management movement strategies), psychological pain management (cognitive behavioural approaches). Medication cost Month 1-6: AUD 60/month (no intervention yet). Month 7-12: AUD 120/month (stabilised opioid dose, reduced adjunctive agents). Month 13-24: AUD 100/month (gradual deprescribing to minimal pain medication). Average medication cost: AUD 110/month. 24-month medication cost: AUD 2,640. Return-to-work achieved Month 14 (2-month earlier return = AUD 2,000 cost reduction). Total 24-month cost: AUD 5,840 plus intervention cost AUD 1,200 = AUD 7,040. Net cost benefit: AUD 16,360 minus AUD 7,040 = AUD 9,320 savings.

Timing of Intervention and Cost Escalation Curve

Early Intervention (Months 1-3 Post-Injury)

Medication review conducted within 3 months of injury initiation identifies problematic patterns (opioid dependency risk, cascade prescribing beginning) early. Early intervention prevents cost escalation before it compounds. Cost savings typically 40-60 percent of unmanaged claim costs.

Intermediate Intervention (Months 4-12 Post-Injury)

Medication review at 6-12 months addresses established polypharmacy or escalating medication costs. Intervention at this stage prevents further escalation but cannot recover escalation already incurred. Cost savings typically 20-40 percent of remaining unmanaged trajectory.

Late Intervention (Beyond 12 Months Post-Injury)

Late medication review addresses heavily established medication patterns and psychological/physical dependence on medications. Deprescribing becomes more challenging, prescriber resistance increases, claimant compliance decreases. Cost savings limited to 10-20 percent of ongoing medication costs.

Beyond Direct Cost: Intangible Cost of Inaction

Claimant Quality of Life

Unmanaged medication risk creates substantial quality of life degradation: cognitive impairment limiting daily activities, side effects reducing physical participation, medication dependence creating psychological distress, and extended claim disability preventing social and work role participation. These intangible harms are often overlooked in cost analysis but create significant human suffering.

Insurer-Claimant Relationship Deterioration

When medication-related complications (falls, hospitalisations, psychological deterioration) occur under insurer's watch without medication intervention, claimant may perceive insurer negligence. This deteriorates insurer-claimant relationship, increasing dispute risk and legal liability exposure.

Prescriber Liability Exposure

If medication-related harm (overdose, falls, medication interaction) occurs in claim where medication risk was identified but not managed, insurer may face liability arguments. Documentation of identified medication risk without intervention creates liability exposure if subsequent medication-related harm occurs.

Exception Cases: When Medication Review May Not Be Cost-Effective

Short Claim Duration Scenarios

In anticipated short-duration claims (expected closure within 2-3 months), medication review may not be cost-effective because medication escalation does not have time to develop significantly. However, even short claims can benefit from medication review if claimant is on high-cost or high-risk medications (opioids, benzodiazepines).

Minimal Medication Burden

Claimants on 1-2 medications with stable regimen and no escalation signals may not require medication review. However, review cost-benefit calculation is marginal in these cases; review cost is essentially wasted on low-risk populations.

Complex Psychosocial Situations

In claims where claimant is actively litigating, medication review recommendations may not be implemented due to claimant non-compliance or dispute environment. In these cases, medication review cost-benefit is reduced. However, documentation of medication risk identified and recommendations made still provides liability protection if future harm occurs.

Cost Benefit Decision Framework for Claim Managers

Request Medication Review If:

• Claim expected duration exceeds 6 months
• Three or more chronic medications prescribed
• Opioid or benzodiazepine therapy ongoing or anticipated
• Medication cost escalation noted (doses increasing, new agents added)
• Medication-related adverse events occurring (falls, cognitive changes)
• Return-to-work delayed or functional recovery plateaued
• Prescriber-prescribed specialist medication (GLP-1, medicinal cannabis, etc.)

Consider Medication Review Timing:

Early intervention (within 3-6 months) provides maximum ROI. If claim is anticipated to exceed 12 months duration and medication complexity is present, medication review is financially prudent within first 6 months post-injury.

Conclusion

Unmanaged medication risk creates exponential cost escalation in insurance claims. Early medication intervention, despite upfront investment cost, provides substantial return on investment through prevented cost escalation, reduced claim duration, and improved functional outcomes. Claim managers treating medication review as discretionary cost should reconsider; medication review should be viewed as essential cost management tool in claims projected to exceed 6-month duration. The cost of inaction in medication management consistently exceeds the cost of early intervention by 2 to 10 times.